GlobeNewswire: Evolus Contains the last 10 of 102 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:54:36ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/11/09/2330429/0/en/Evolus-Announces-Participation-in-November-Investment-Conferences.html?f=22&fvtc=4&fvtv=46785Evolus Announces Participation in November Investment Conferences2021-11-09T13:30:00Z<![CDATA[NEWPORT BEACH, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in two investment conferences in November.]]>https://www.globenewswire.com/news-release/2021/11/02/2325338/0/en/Evolus-Reports-Third-Quarter-2021-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=46785Evolus Reports Third Quarter 2021 Results and Provides Business Update2021-11-02T12:03:00Z<![CDATA[NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.]]>https://www.globenewswire.com/news-release/2021/11/02/2325336/0/en/Evolus-Initiates-Phase-II-Program-with-Extra-Strength-Dose-for-Extended-Duration.html?f=22&fvtc=4&fvtv=46785Evolus Initiates Phase II Program with “Extra Strength” Dose for Extended Duration2021-11-02T12:01:00Z<![CDATA[NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it has initiated a clinical program to study an “extra strength” dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), its flagship neurotoxin product and first and only neurotoxin dedicated exclusively to aesthetics.]]>https://www.globenewswire.com/news-release/2021/11/01/2324833/0/en/Evolus-Announces-Appointment-of-Jessica-Novak-as-Senior-Vice-President-Human-Resources.html?f=22&fvtc=4&fvtv=46785Evolus Announces Appointment of Jessica Novak as Senior Vice President, Human Resources2021-11-01T20:10:00Z<![CDATA[NEWPORT BEACH, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that Jessica Novak, SPHR has joined the company as Senior Vice President, Human Resources where she will oversee global efforts to expand, retain and develop an entrepreneurial team bringing innovative products and marketing solutions to the aesthetics industry.]]>https://www.globenewswire.com/news-release/2021/10/22/2319195/0/en/Evolus-to-Report-Third-Quarter-2021-Results-and-Provide-Business-Update.html?f=22&fvtc=4&fvtv=46785Evolus to Report Third Quarter 2021 Results and Provide Business Update2021-10-22T13:00:00Z<![CDATA[NEWPORT BEACH, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its third quarter 2021 financial results and provide a business update on Tuesday, November 2, 2021, prior to the open of the U.S. financial markets.]]>https://www.globenewswire.com/news-release/2021/09/02/2290922/0/en/Evolus-Announces-Participation-in-September-Investment-Conferences.html?f=22&fvtc=4&fvtv=46785Evolus Announces Participation in September Investment Conferences2021-09-02T13:00:00Z<![CDATA[NEWPORT BEACH, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in two investment conferences in September.]]>https://www.globenewswire.com/news-release/2021/08/04/2274980/0/en/Evolus-Reports-Second-Quarter-2021-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=46785Evolus Reports Second Quarter 2021 Results and Provides Business Update2021-08-04T20:05:00Z<![CDATA[Record Quarter: Net Revenue Grew 235% Year-over-Year to $26.1 Million]]>https://www.globenewswire.com/news-release/2021/07/22/2267395/0/en/Evolus-to-Report-Second-Quarter-2021-Results-and-Provide-Business-Update.html?f=22&fvtc=4&fvtv=46785Evolus to Report Second Quarter 2021 Results and Provide Business Update2021-07-22T13:00:00Z<![CDATA[NEWPORT BEACH, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its second quarter 2021 financial results and provide a business update on Wednesday, August 4, 2021, after the close of the U.S. financial markets.]]>https://www.globenewswire.com/news-release/2021/06/30/2255715/0/en/Evolus-Announces-Appointment-of-David-K-Erickson-as-Vice-President-Investor-Relations.html?f=22&fvtc=4&fvtv=46785Evolus Announces Appointment of David K. Erickson as Vice President, Investor Relations2021-06-30T13:00:00Z<![CDATA[NEWPORT BEACH, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that David K. Erickson has joined the company as Vice President, Investor Relations where he will be responsible for developing, implementing and managing a comprehensive and strategic investor relations program.]]>https://www.globenewswire.com/news-release/2021/06/24/2252668/0/en/Peer-Reviewed-Article-Highlights-Efficacy-and-Safety-of-Jeuveau-in-Patients-with-Skin-of-Color.html?f=22&fvtc=4&fvtv=46785Peer Reviewed Article Highlights Efficacy and Safety of Jeuveau® in Patients with Skin of Color2021-06-24T13:00:00Z<![CDATA[NEWPORT BEACH, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced a peer reviewed journal article was published in Dermatologic Surgery (April 2021) highlighting the efficacy and safety of prabotulinumtoxinA (Jeuveau®) for the treatment of moderate to severe glabellar lines, also known as frown lines between the eyes, in adult patients with Skin of Color (SOC).]]>